Abstract:As recombinant tissue plasminogen activator is the only drug approved for the clinical treatment of acute ischemic stroke, there is an urgent unmet need for novel stroke treatments. Endogenous defense mechanisms against stroke may hold the key to new therapies for stroke. A large number of studies suggest that nicotinamide phosphoribosyl-transferase (NAMPT is an attractive candidate to improve post-stroke recovery. NAMPT is a multifunctional protein and plays important roles in immunity, metabolism, aging, inflammation, and stress responses. NAMPT exists in both the intracellular and extracellular space. As a rate-limiting enzyme, the intracellular form (iNAMPT catalyzes the first step in the biosynthesis of nicotinamide adenine dinucleotide (NAD from nicotinamide. iNAMPT closely regulates energy metabolism, enhancing the proliferation of endothelial cells, inhibiting apoptosis, regulating vascular tone, and stimulating autophagy in disease conditions such as stroke. Extracellular NAMPT (eNAMPT is also known as visfatin (visceral fat-derived adipokine and has pleotropic effects. It is widely believed that the diverse biological functions of eNAMPT are attributed to its NAMPT enzymatic activity. However, the effects of eNAMPT on ischemic injury are still controversial. Some authors have argued that eNAMPT exacerbates ischemic neuronal injury non-enzymatically by triggering the release of TNF-α from glial cells. In addition, NAMPT also participates in several pathophysiological processes such as hypertension, atherosclerosis, and ischemic heart disease. Thus, it remains unclear under what conditions NAMPT is beneficial or destructive. Recent work using in vitro and in vivo genetic/ pharmacologic manipulations, including our own studies, has greatly improved our understanding of NAMPT. This review focuses on the multifaceted and complex roles of NAMPT under both normal and ischemic conditions.

An NAMPT Inhibitor Decreases NAMPT Capture by an Antibody Directed against the 5-Phosphoribosyl-1-Pyrophosphate-Binding Loop: A Rational for an NAMPT Occupancy Assay

Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase

Nicotinamide Phosphoribosyltransferase Inhibitors, Design, Preparation, and Structure–Activity Relationship

The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia

Data from Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors

Structural Basis for Resistance to Diverse Classes of Nampt Inhibitors

Discovery and Characterization of Novel Small-Molecule Inhibitors Targeting Nicotinamide Phosphoribosyltransferase

Drug Discovery Targeting Nicotinamide Phosphoribosyltransferase (NAMPT): Updated Progress and Perspectives

Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death

Discovery of Novel Inhibitors and Fluorescent Probe Targeting Nampt

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).

NAMPT-targeting PROTAC promotes antitumor immunity <i>via</i> suppressing myeloid-derived suppressor cell expansion

Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery

[A Method Based on Endogenous Fluorescence Determination for Screening NAMPT Inhibitors].

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review

Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors

Discovery of Trans-3-(pyridin-3-yl)acrylamide-derived Sulfamides As Potent Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors for the Potential Treatment of Cancer

A Fluorometric Assay for High-Throughput Screening Targeting Nicotinamide Phosphoribosyltransferase

NAMPT: A critical driver and therapeutic target for cancer

Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies

Utilization Of18f-Fluorodeoxyglucose–positron Emission Tomography to Understand the Mechanism of Nicotinamide Phosphoribosyltransferase Inhibitors in Vivo